Last updated: May 14, 2026
Bicillin C-R is an off-patent, legacy injectable penicillin combination used for susceptible bacterial infections. Public disclosure of active late-stage clinical development and current commercial revenue is limited in accessible sources; the practical market outlook is driven by (1) supply continuity for penicillin G benzathine/procaine, (2) guideline-driven demand, (3) substitution to other long-acting penicillins, and (4) payer and hospital formulary decisions rather than patent exclusivity.
What is Bicillin C-R and what active ingredients does it contain?
Bicillin C-R is a combination product of two injectable penicillin components:
- Penicillin G benzathine (long-acting depot fraction)
- Penicillin G procaine (intermediate-acting fraction)
Drug class: Natural penicillins.
Route/dosage form: Intramuscular injection (depot suspension).
Clinical positioning: Treatment of susceptible infections where clinicians use a long-acting penicillin regimen (historically including selected streptococcal infections and other susceptible bacterial infections per label and local practice).
What clinical trials exist for Bicillin C-R, and what is the latest update?
Featured snippet answer: No current, well-indexed late-stage (Phase 3/registrational) clinical trials for “Bicillin C-R” specifically are consistently surfaced in major public trial registries in a way that supports a credible “latest update” statement for ongoing pivotal studies.
Trial evidence base: what’s typically available for this product class
For legacy depot penicillin combinations like benzathine/procaine penicillin, much of the evidentiary footprint is historical:
- Microbiology and susceptibility-based rationale
- Pharmacokinetic and bioavailability considerations for depot formulations
- Older comparative or supportive studies rather than modern Phase 3 programs
How to interpret “clinical trials update” in this asset
For off-patent injectables, “updates” in practice usually come from:
- New guideline recommendations for streptococcal disease prophylaxis/therapy
- Safety communications for penicillin-class risks (hypersensitivity, anaphylaxis)
- Shortages or supply reallocations that affect administered volume more than trial pipelines
Practical take: Market changes for Bicillin C-R are more likely to track supply and guideline utilization than new trial readouts.
What patents protect Bicillin C-R, and how strong is the patent estate?
Featured snippet answer: Bicillin C-R is a legacy penicillin combination with an evidentiary basis that strongly indicates the core product is off-patent in most relevant jurisdictions; any remaining protection is more likely to be narrow (secondary formulation/manufacturing improvements) or tied to specific branded labeling/packaging rather than the fundamental active ingredient combination.
Likely patent landscape structure for legacy penicillins
For older combination injectables:
- The fundamental chemistry and composition of known penicillins are typically early-dated and expired.
- Current exclusivity, if any, is usually not composition-based but may include:
- manufacturing process improvements
- specific formulation stability claims
- packaging or method-of-use claims for particular regimens
How patent strength affects business decisions
When patent estate strength is low:
- Generic and authorized equivalents dominate procurement options.
- Value shifts to supply reliability, contract pricing, and distribution coverage.
- Litigation risk is more about manufacturing site and label carve-outs than blockbuster exclusivity.
Note: Without an Orange Book listing and listed patents for a specific NDA/ANDA identifier tied to Bicillin C-R in accessible records here, a definitive patent-number and expiry table cannot be produced from the supplied prompt.
When does Bicillin C-R lose exclusivity, and what Orange Book status applies?
Featured snippet answer: Bicillin C-R is treated commercially as an established generic/authorized equivalent class; any “exclusivity” that could have existed is not expected to be operative in the current market.
What “Orange Book status” usually means for this type of product
For older injectables, Orange Book entries (if present) often reflect:
- old patents that have expired
- patent listings that no longer prevent generic competition
No actionable Orange Book table can be generated here because the prompt does not provide the precise NDA/ANDA reference number and the underlying patent listing content needed for a complete status mapping.
What formulations or dosage strengths of Bicillin C-R exist, and what matters for competition?
Bicillin C-R is sold as an IM depot suspension with fixed proportions of benzathine and procaine penicillin components. Competitive differentiators in depot penicillin markets commonly include:
- Concentration and suspension characteristics (clinician handling)
- Stability and shelf life (distribution planning)
- Needle compatibility and injection volume (administration efficiency)
- Supply continuity (hospital purchasing systems prioritize delivery reliability)
Market participants typically treat substitutes as functionally equivalent if they share:
- the same active ingredient combination
- comparable dosing instructions
- compatible manufacturing controls
What generic entry risks exist for Bicillin C-R?
Featured snippet answer: The main “entry risk” is not a patent-wall barrier. It is a manufacturing and supply execution risk for any new entrant or authorized generic provider of depot penicillin combinations.
What can still block or delay market participation
Even with expired patents:
- GMP manufacturing scale and filtration/lyophilization-related process maturity can be a barrier
- Supply constraints for penicillin G starting materials can drive allocation behavior
- Labeling and clinical instructions must meet regulatory requirements
What patent litigation affects Bicillin C-R?
Featured snippet answer: Bicillin C-R is not associated with ongoing, widely publicized patent-infringement events at a level that supports an actionable litigation summary from the supplied prompt.
How litigation typically shows up for legacy injectables
When litigation does occur for established generics, it is often:
- centered on method-of-use, REMS-adjacent label changes, or narrow formulation claims
- driven by ANDA-to-NDA patent listing disputes rather than composition novelty
No litigation docket mapping can be provided here without the specific NDA/ANDA and patent listing set.
How does Bicillin C-R compare with other long-acting penicillin products?
In practice, decision-making compares Bicillin C-R against other long-acting penicillin formulations (often by:
- dosing schedule
- injection volume
- duration of action
- availability)
Practical substitution factors
- Clinical protocol fit (hospital pathways and national guideline alignment)
- Availability and cost for depot injectables
- Administration logistics (nursing time, stock on hand)
What is the FDA regulatory pathway status for Bicillin C-R and related equivalents?
Featured snippet answer: Bicillin C-R is an approved marketed injectable under an established regulatory history; contemporary new entrants for the same actives generally use generic (ANDA) or authorized equivalent pathways if eligible.
What matters for regulatory/commercial timing
For older, off-patent products:
- Regulatory timelines are usually shorter than for novel entities
- Market impact is more sensitive to supply chain and manufacturing capacity than to regulatory exclusivity
Market analysis: who buys Bicillin C-R and why?
Featured snippet answer: Purchasers are dominated by hospitals, public health programs, and inpatient/outpatient clinics that administer depot penicillin regimens under local stewardship and guideline protocols.
Demand drivers
- Guideline utilization for susceptible bacterial infections where long-acting penicillin is preferred or recommended
- Seasonal infection patterns and periodic public health emphasis
- Stock and allocation due to penicillin-class supply fluctuations
- Payer reimbursement and hospital contract pricing
Demand suppressors
- Shift toward alternative antibiotic classes in some protocols due to perceived risks or availability
- Inventory management constraints that move clinicians to whichever long-acting penicillin is reliably in stock
- Prescriber preference changes with emerging resistance patterns and stewardship policies
Market projection for Bicillin C-R: base case, upside, downside scenarios
Featured snippet answer: For an off-patent injectable, the most realistic projections are range-based and tied to supply stability and formulary share rather than patent-driven growth. A robust projection requires current unit volumes or revenue figures, which are not provided in the prompt.
Projection framework that fits legacy depot penicillin markets
Key variables to model:
- Annual treatment volume for guideline-aligned indications
- Market share vs alternatives (other long-acting penicillins, penicillin V/oral regimens where applicable)
- Net price erosion from generic competition
- Supply availability (stockouts can cap administered units)
- Switching friction (how quickly formularies adopt substitute products)
Practical business implication
Even without exact numbers, the market is typically:
- mature
- price-competitive
- supply-sensitive
- bounded by clinical use protocols
Geographic coverage: where is Bicillin C-R most likely to be competitive?
Featured snippet answer: Competition is primarily within countries where long-acting benzathine/procaine penicillin products are included in essential medicines lists, formularies, and national treatment guidance.
Competitive intensity expectations
- High in markets with multiple authorized equivalents
- Lower where depot penicillin supply is limited and procurement is constrained by manufacturer availability
Manufacturing and IP barriers: what blocks entrants besides patents?
Featured snippet answer: For depot penicillin injectables, the binding constraints are manufacturing execution, compliance, and supply-chain continuity.
Non-IP barriers that affect speed-to-market
- Scaling the depot suspension process with consistent particle characteristics
- Sterility assurance and batch-to-batch uniformity
- Regulatory inspection readiness
- Raw material sourcing for penicillin G derivatives
Key Takeaways
- Bicillin C-R is a long-acting depot penicillin combination (benzathine + procaine) used as an established injectable therapy.
- A credible “latest clinical trials update” for Phase 3/registrational activity is not supported by the prompt’s provided dataset and the legacy nature of the product.
- Any remaining IP protections, if present, are unlikely to function as major market exclusivity drivers; commercial outcomes depend more on supply continuity and formulary share.
- Market growth is more likely to track guideline-driven utilization and manufacturing availability than new scientific differentiation.
- For projections, a business-useful model should be volume-and-supply driven rather than patent-expiration driven.
FAQs
- Is Bicillin C-R considered interchangeable with other benzathine/procaine penicillin injectables?
- Do shortages of penicillin G benzathine or procaine affect Bicillin C-R availability and hospital utilization?
- What types of regulatory filings are typically used by entrants seeking equivalents of legacy penicillin depot products?
- How do hospital formularies decide between long-acting penicillin injections and oral antibiotic alternatives?
- What safety and administration risks most commonly drive changes in prescribing behavior for depot penicillins?
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- ClinicalTrials.gov. (n.d.). ClinicalTrials.gov. U.S. National Library of Medicine. https://clinicaltrials.gov/
- World Health Organization. (n.d.). WHO Model List of Essential Medicines. World Health Organization. https://www.who.int/medicines/publications/essentialmedicines/en/
